# EDGAR Filing Document

**Accession Number:** 0001438569
**File Stem:** 0001104659-25-121424
**Filing Date:** 2025-12
**Character Count:** 4174
**Document Hash:** 5dbe038aef7eeebda3a087072d9261d3
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-121424.hdr.sgml**: 20251216

**ACCESSION NUMBER**: 0001104659-25-121424

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20251216

**FILED AS OF DATE**: 20251216

**DATE AS OF CHANGE**: 20251216

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Grifols SA
- **CENTRAL INDEX KEY:** 0001438569
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-35193
- **FILM NUMBER:** 251573544

**BUSINESS ADDRESS:**
- **STREET 1:** 1585 BROADWAY
- **STREET 2:** SUITE 2376
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10036
- **BUSINESS PHONE:** 212-969-3335

**MAIL ADDRESS:**
- **STREET 1:** 1585 BROADWAY
- **STREET 2:** SUITE 2376
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10036

**UNITED STATES<br> SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16<br> UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of December 2025**

**Commission File No. 001-35193**

**Grifols, S.A.**

(Translation of registrant's name into English)

**Avinguda de la Generalitat, 152-158**

**Parc de Negocis Can Sant Joan**

**Sant Cugat del Valles 08174**

**Barcelona, Spain**

(Address of registrant's principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ⌧ Form 40-F ◻

**Grifols, S.A.**

**TABLE OF CONTENTS**

---

| | | |
|:---|:---|:---|
| **Item** | **Item** | **Sequential Page Number** |
| [1.](#a_001) | [Other Relevant Information, dated December 16, 2025](#a_001) | [3](#a_001) |

---

---

| | |
|:---|:---|
| ![](tm2533540d1_6kimg001.jpg) | **Grifols, S.A.<br>** <br> Avinguda de la Generalitat 152-158 <br> 08174 Sant Cugat del Vallès <br> Barcelona - SPAIN<br>Tel. [34] 935 710 500<br> Fax [34] 935 710 267<br><u>www.grifols.com</u> |

---

Pursuant to the provisions of Article 227 of Law 6/2023 of March 17, on Securities Markets and Investment Services, Grifols, S.A. ("**Grifols**" or the "**Company"**) hereby informs about the following

**OTHER RELEVANT INFORMATION**

Grifols informs that on December 11, 2025, the European Medicines Agency (EMA) has issued the Certificate of Compliance with Community legislation for the plasma supplied by Grifols Egypt for Plasma Derivatives (GEPD), the joint venture established in 2020 jointly between Grifols and Egypt's National Service Projects Organization.

This certification has been granted after the quality inspection to the plasma centers owned by GEPD and after the review by the EMA that all procedures, selection of donors, plasma obtention methods, quality controls, and storage (among others) comply with the quality and security standards required by European legislation.

This certification will allow not only to manufacture plasma products by GEPD but also to commercialize them throughout Europe and in all countries that follow EMA legislation.

The achievement of this certification from the EMA for the Egyptian plasma is a huge milestone for the Company and Grifols has been the first plasma company in accomplishing this significant step.

This recognition positions Egypt as the first country in Africa and the Middle East to operate a fully integrated plasma collection and processing system that meets the strictest international standards.

---

| |
|:---|
| In Barcelona, on 16 December 2025 |
| Núria Martín Barnés |
| Secretary to the Board of Directors |

---

**<u>SIGNATURES</u>**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.

---

| | | |
|:---|:---|:---|
| Grifols, S.A. | Grifols, S.A. | Grifols, S.A. |
| By: | /s/ David I. Bell | /s/ David I. Bell |
|  | Name: | David I. Bell |
|  | Title: | Authorized Signatory |

---

Date: December 16, 2025